Is capmatinib domestically produced or imported?

Capmatinib (Capmatinib) was originally developed by Novartis and launched in the international market. Therefore, its original version was an imported drug after it was launched in China, not a domestic drug. Capmatinib, a targeted therapy targeting MET gene mutations and amplifications, has been approved in multiple countries for the treatment of patients with non-small cell lung cancer (NSCLC) whose tumor mutations lead to mesenchymal-epithelial transfer (MET) exon 14 skipping, as detected by a U.S. Food and Drug Administration (FDA)-approved test.

In clinical practice, doctors will choose appropriate treatment options based on the patient's tumor condition and genetic testing results. Capmatinib remains an important treatment option for patients with non-small cell lung cancer diagnosed with MET gene mutations or amplifications. It is currently understood that the standard dose is 400 mg taken orally twice daily.

Imported drugs generally undergo strict supervision and evaluation to ensure their efficacy and safety. In China, the registration and approval procedures for imported drugs are also very strict to protect the rights and safety of patients. After a series of clinical trials and review processes, capmatinib was finally successfully launched in China in 2024 under the trade name Tourad.

The launch of capmatinib marks another solid step in the treatment of lung cancer in China, providing new treatment options and survival opportunities for many patients with lung cancer with METex14 skip mutations. As a highly selective small molecule MET inhibitor, capmatinib plays a therapeutic role by inhibiting the tyrosine kinase activity of MET receptors and blocking the proliferation, survival and metastasis of tumor cells.